Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Division of Infectious Diseases, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Infect Control Hosp Epidemiol. 2020 Aug;41(8):914-920. doi: 10.1017/ice.2020.183. Epub 2020 May 29.
Fluoroquinolones (FQs) and extended-spectrum cephalosporins (ESCs) are associated with higher risk of Clostridioides difficile infection (CDI). Decreasing the unnecessary use of FQs and ESCs is a goal of antimicrobial stewardship. Understanding how prescribers perceive the risks and benefits of FQs and ESCs is needed.
We conducted interviews with clinicians from 4 hospitals. Interviews elicited respondent perceptions about the risk of ESCs, FQs, and CDI. Interviews were audio recorded, transcribed, and analyzed using a flexible coding approach.
Interviews were conducted with 64 respondents (38 physicians, 7 nurses, 6 advance practice providers, and 13 pharmacists). ESCs and FQs were perceived to have many benefits, including infrequent dosing, breadth of coverage, and greater patient adherence after hospital discharge. Prescribers stated that it was easy to make decisions about these drugs, so they were especially appealing to use in the context of time pressures. They described having difficulty discontinuing these drugs when prescribed by others due to inertia and fear. Prescribers were skeptical about targeting specific drugs as a stewardship approach and felt that the risk of a negative outcome from under treatment of a suspected bacterial infection was a higher priority than the prevention of CDI.
Prescribers in this study perceived many advantages to using ESCs and FQs, especially under conditions of time pressure and uncertainty. In making decisions about these drugs, prescribers balance risk and benefit, and they believed that the risk of CDI was acceptable in compared with the risk of undertreatment.
氟喹诺酮类药物(FQs)和扩展谱头孢菌素类药物(ESCs)与艰难梭菌感染(CDI)的风险增加相关。减少不必要的 FQs 和 ESCs 的使用是抗菌药物管理的目标。了解临床医生如何看待 FQs 和 ESCs 的风险和益处是必要的。
我们对来自 4 家医院的临床医生进行了访谈。访谈内容包括受访者对 ESC、FQs 和 CDI 风险的看法。访谈采用灵活的编码方法进行录音、转录和分析。
共对 64 名受访者(38 名医生、7 名护士、6 名高级执业医师和 13 名药剂师)进行了访谈。ESCs 和 FQs 被认为有许多好处,包括减少给药次数、广泛的覆盖范围以及患者在出院后的更高依从性。临床医生表示,他们很容易就这些药物做出决策,因此在时间压力下使用这些药物特别有吸引力。他们描述说,由于惯性和恐惧,当其他医生开这些药物时,他们很难停止使用。临床医生对将特定药物作为管理措施持怀疑态度,并认为治疗疑似细菌感染的不良后果的风险比预防 CDI 的风险更为重要。
本研究中的临床医生认为使用 ESCs 和 FQs 有很多优势,尤其是在时间压力和不确定性的情况下。在做出这些药物的决策时,临床医生权衡风险和收益,他们认为与治疗不足的风险相比,CDI 的风险是可以接受的。